Shiyao Liu

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

I. Pastan, J. Delgado, P. Zinzani, 2021, Journal of Hematology & Oncology.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

G. Linette, A. Ribas, H. Tawbi, 2017, Melanoma research.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Accuracy of Raman spectroscopy in discrimination of nasopharyngeal carcinoma from normal samples: a systematic review and meta-analysis

Lei Cheng, Hongyu Jin, Yingzhe Zhang, 2019, Journal of Cancer Research and Clinical Oncology.

1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

A. Drilon, M. Ahn, R. Doebele, 2020 .

Golgi Phosphoprotein 73: The Driver of Epithelial-Mesenchymal Transition in Cancer

Hongchuan Jin, Shiyao Liu, Xin-yao Hu, 2021, Frontiers in Oncology.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

T. Burns, R. Heist, Y. Murciano-Goroff, 2023, Cancer Research.

1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis

A. Drilon, M. Ahn, R. Doebele, 2020 .